Biotech M&A speculation involving Incyte, AbbVie, and Viking Therapeutics, with three Nasdaq-listed names under watch.
1 report, 1 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biotech M&A speculation involving Incyte, AbbVie, and Viking Therapeutics, with three Nasdaq-listed names under watch.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Incyte acquired Vega Therapeutics to diversify its late-stage pipeline.Sub-event
Incyte and AbbVie are mentioned in biotech M&A context alongside Viking Therapeutics.1 source
Keep exploring
The entities involved
-
Incyte
American pharmaceutical company
-
AbbVie
pharmaceutical company
-
Viking Therapeutics
company in San Diego, United States
Nothing else this week.
Related events
- AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.